The 21st Century Cures Act: Modernizing Healthcare in New York and Beyond

Sunday, October 4, 2015

Over the past two decades, healthcare innovation has advanced at a rapid speed. Breakthroughs, from the mapping of the human genome to the evolution of personalized medicine, are changing the way diseases are treated, managed, and cured. While the bioscience and medical technology (Bio/Med) industry has made substantial advancements, our country’s legal and regulatory systems have failed to keep up with the pace of innovation in this industry. For suffering patients who need these new healthcare innovations, there is no time to waste.

Less than three months ago, in July 2015, the United States House of Representatives approved the 21st Century Cures Act. This legislation will help modernize the healthcare innovation infrastructure, incorporate patient perspectives into the drug and device approval process, support advances in personalized medicine, streamline clinical trials and provide more resources to support research. This act would also deliver $8.75 billion to the National Institutes of Health (NIH) to fund areas of invaluable medical research at NIH, as well as at universities through grant programs. The act would vastly improve the Bio/Med industry by more quickly moving potential treatments from the lab to the clinic.

The 21st Century Cures Act will enable those in the Bio/Med industry to continue to innovate and develop the lifesaving treatments that suffering patients desperately need. It will also have a direct impact on the Western New York economy by allowing for new research, more clinicians, and exciting new technologies.

To help cure rare diseases, both government and the Bio/Med industry need to work together. The 21st Century Cures Act establishes the framework needed for increased collaboration between the two sectors. It is now time we take the necessary steps towards curing and treating the thousands of diseases we don’t have an answer for yet.

On October 15, 2015, MedTech 2015 will be hosting a breakfast for Bio/Med leaders from all over New York regarding their thoughts on how to improve our state’s healthcare ecosystem. Together, we will advocate for the 21st Century Cures Act. The legislation incentivizes innovation to defeat disease, and will provide new hope to patients and their families.

Ultimately, both government and the Bio/Med industry have the same goal – to ensure that people receive the cures and therapies they need. We are committed to the health and wellness of this region and are confident the 21st Century Cures Act is a large step in the right direction. Together we can change the way we fight rare diseases, helping to save lives and modernize the healthcare industry.

Congressman Chris Collins represents New York’s 27th Congressional District in the House of Representatives and Jessica Crawford is President of MedTech, a non-profit trade association representing New York’s bioscience and medical technology industry.

View All News »